Press release
Insulin Resistance Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight
Insulin Resistance - Pipeline Insight, 2026
DelveInsight's "Insulin Resistance - Pipeline Insight, 2026" report provides comprehensive insights about 20+ companies developing 20+ pipeline drugs in the Insulin Resistance pipeline landscape. It covers the Insulin Resistance pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.
Explore the latest breakthroughs in the Insulin Resistance treatment landscape. Learn more about the evolving Insulin Resistance pipeline today @ https://www.delveinsight.com/report-store/insulin-resistance-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr
Key Takeaways from the Insulin Resistance Pipeline Report
*
In December 2025, Eli Lilly and Company reported encouraging topline findings from its Phase III TRIUMPH-4 study evaluating retatrutide, underscoring its potential to enhance insulin sensitivity through its triple-agonist mechanism of action.
*
In September 2025, Innovent Biologics, Inc. announced that China's National Medical Products Administration (NMPA) has approved mazdutide for metabolic conditions including insulin resistance.
*
In June 2025, AdipoPharma's PATAS, an innovative adipocyte-targeted, disease-modifying insulin sensitizer, was highlighted at the ADA 85th Annual Meeting, with clinical development anticipated in late 2025.
*
DelveInsight's Insulin Resistance Pipeline Insight report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Insulin Resistance treatment.
*
The leading Insulin Resistance companies include Corbus Pharmaceuticals Holdings, Inc., Kura Oncology, Inc, SCOHIA Pharma Inc, Atrogi, YUNOVIA CO.,LTD., PegBio, Eli Lilly and Company, Tonix Pharma, Pfizer, OrsoBio, Dompe Farmaceutici, GlaxoSmithKline, J. Uriach and Company, Boehringer Ingelheim, Genfit, Novartis, Daiichi Sankyo, Inc., and others.
*
Promising Insulin Resistance therapies include CRB-913, Ziftomenib, SCO-240, ATR-258, ID110521156, Visepegenatide (PB-119), Retatrutide, TNX-1900, Steglatro, TLC-3595, Ladarixin, Avandia, Triflusal (DCI), MICARDIS (telmisartan), U-500 insulin, Vildagliptin, GFT505, Nateglinide, Olmesartan medoxomil, and others.
Download for updates and the latest revolution in Insulin Resistance care @ Insulin Resistance Clinical Trials Assessment [https://www.delveinsight.com/sample-request/insulin-resistance-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Insulin Resistance Emerging Drugs Profile
*
Retatrutide: Eli Lilly and Company
Retatrutide is a novel triple-agonist peptide that activates the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This unique mechanism of action enhances insulin sensitivity, promotes weight loss, and improves glycemic control. The drug works by targeting multiple metabolic pathways simultaneously, providing comprehensive metabolic regulation. In December 2025, Eli Lilly reported encouraging Phase III TRIUMPH-4 study results demonstrating significant improvements in insulin sensitivity. Retatrutide is currently being evaluated in Phase III clinical trials to treat insulin resistance and metabolic disorders.
*
Visepegenatide (PB-119): PegBio
Visepegenatide (PB-119) is a long-acting GLP-1 receptor agonist designed to improve insulin sensitivity and glycemic control in patients with metabolic disorders. The drug employs PEGylation technology to extend its half-life, allowing for less frequent dosing while maintaining therapeutic efficacy. By activating GLP-1 receptors, it enhances insulin secretion in a glucose-dependent manner and suppresses glucagon release, thereby improving overall metabolic function. The drug is currently in clinical development for the treatment of insulin resistance.
*
CRB-913: Corbus Pharmaceuticals Holdings, Inc.
CRB-913 is a novel therapeutic candidate targeting inflammatory pathways associated with insulin resistance. The compound modulates immune responses and metabolic signaling to enhance insulin sensitivity in peripheral tissues. The drug's mechanism involves reducing chronic low-grade inflammation, which is a key driver of insulin resistance in metabolic syndrome and type 2 diabetes. CRB-913 is currently being evaluated in clinical trials for the treatment of insulin resistance and related metabolic conditions.
For more information on the Insulin Resistance Emerging Drugs Profile, download DelveInsight's comprehensive Insulin Resistance Pipeline Insight report [https://www.delveinsight.com/sample-request/insulin-resistance-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The Insulin Resistance Pipeline Report Provides
*
Detailed insights about companies developing therapies for Insulin Resistance, with aggregate therapies developed by each company.
*
Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Insulin Resistance treatment.
*
Insulin Resistance companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Insulin Resistance drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Insulin Resistance market.
Learn more about Insulin Resistance Drugs opportunities in our comprehensive Insulin Resistance pipeline report @ Insulin Resistance Unmet Needs [https://www.delveinsight.com/sample-request/insulin-resistance-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Insulin Resistance Companies
There are 20+ key companies, such as Corbus Pharmaceuticals Holdings, Inc., Kura Oncology, Inc, SCOHIA Pharma Inc, Atrogi, YUNOVIA CO.,LTD., PegBio, Eli Lilly and Company, Tonix Pharma, Pfizer, OrsoBio, Dompe Farmaceutici, GlaxoSmithKline, J. Uriach and Company, Boehringer Ingelheim, Genfit, Novartis, Daiichi Sankyo, Inc., Exscien Corp, Glycomantra Inc, Hanmi Pharmaceuticals Co Ltd, NorthSea Therapeutics BV, Amolyt Pharma, Amryt Pharma Plc, CohBar Inc, Lixte Biotechnology Holdings Inc, The Healthy Aging Co, Trigemina Inc, and others, developing therapies for Insulin Resistance, with Eli Lilly and Company having its Insulin Resistance drug candidate in the most advanced Phase III stage.
DelveInsight's Insulin Resistance pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
*
Oral
*
Intravenous
*
Subcutaneous
Insulin Resistance products have been categorized under various Molecule types such as:
*
Small molecule
*
Cell Therapy
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Discover the latest advancements in Insulin Resistance treatment by visiting our website. Stay informed @ Insulin Resistance Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/insulin-resistance-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Scope of the Insulin Resistance Pipeline Report
*
Coverage: Global
*
Insulin Resistance companies: Corbus Pharmaceuticals Holdings, Inc., Kura Oncology, Inc, SCOHIA Pharma Inc, Atrogi, YUNOVIA CO.,LTD., PegBio, Eli Lilly and Company, Tonix Pharma, Pfizer, OrsoBio, Dompe Farmaceutici, GlaxoSmithKline, J. Uriach and Company, Boehringer Ingelheim, Genfit, Novartis, Daiichi Sankyo, Inc., and others
*
Insulin Resistance Therapies: CRB-913, Ziftomenib, SCO-240, ATR-258, ID110521156, Visepegenatide (PB-119), Retatrutide, TNX-1900, Steglatro, TLC-3595, Ladarixin, Avandia, Triflusal (DCI), MICARDIS (telmisartan), U-500 insulin, Vildagliptin, GFT505, Nateglinide, Olmesartan medoxomil, and others.
*
Insulin Resistance Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
*
Insulin Resistance Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Table of Contents
*
Introduction
*
Executive Summary
*
Insulin Resistance: Overview
*
Pipeline Therapeutics
*
Therapeutic Assessment
*
Insulin Resistance - DelveInsight's Analytical Perspective
*
Late Stage Products (Phase III)
*
Mid Stage Products (Phase II)
*
Early Stage Products (Phase I)
*
Preclinical and Discovery Stage Products
*
Inactive Products
*
Insulin Resistance Key Companies
*
Insulin Resistance Key Products
*
Insulin Resistance Unmet Needs
*
Insulin Resistance Market Drivers and Barriers
*
Insulin Resistance Future Perspectives and Conclusion
*
Insulin Resistance Analyst Views
*
Appendix
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=insulin-resistance-pipeline-expands-as-20-pharma-companies-progress-novel-therapies-toward-market-entry-finds-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Insulin Resistance Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight here
News-ID: 4396244 • Views: …
More Releases from ABNewswire
Carter & Tucker Bath Remodeling Explains What Homeowners Should Consider Before …
Carter & Tucker Bath Remodeling is helping Lynnwood, Washington homeowners make informed remodeling decisions by highlighting the key factors to consider before beginning a bathroom renovation. The company explains why careful planning, quality materials, professional bathroom design, bathtub installation, and tile installation all contribute to a successful bathroom remodel and long-term property value.
Lynnwood, WA - As homeowners across the Seattle metropolitan area continue investing in home improvements throughout 2026, Carter…
Queen Creek Homeowners Planning a Whole Home Remodel Often Underestimate How Sha …
The common assumption that a whole home remodel can be priced by adding together separate room projects overlooks the flooring, lighting, finishes, circulation, storage, and construction coordination shared across those rooms.
July 29, 2026 - Queen Creek has experienced substantial residential growth, with the U.S. Census Bureau estimating a 2025 population of 89,770, up 51.4% from the town's 2020 population estimate base. The community also has a 90.2% owner-occupied housing rate,…
Chris Grose Chiropractic Continues Offering Spinal Decompression Therapy in Beck …
Chris Grose Chiropractic in Beckley, WV, continues offering non-surgical spinal decompression therapy for adults managing herniated discs and spinal conditions. Led by Dr. Chris Grose, the practice uses specialized mechanical traction to gently relieve nerve pressure and support disc recovery. This conservative, drug-free program gives Beckley and Southern West Virginia residents an effective alternative to surgery for chronic back and neck pain.
BECKLEY, WV - Chris Grose Chiropractic continues to provide…
Orchard Manor Expands Nurse-Led Memory Care and Specialized Respite Support in F …
Orchard Manor, a registered-nurse-owned senior living community in Farmington Hills, MI, is expanding its dedicated memory care and short-term respite programs. Designed as an intimate small-group care home, Orchard Manor provides round-the-clock clinical oversight in a warm, domestic setting. The expansion ensures local families have access to compassionate, individualized care for loved ones with memory loss.
FARMINGTON HILLS, MI - As the demand for specialized, low-ratio senior care grows across Oakland…
More Releases for Insulin
Insulin Delivery System Advancement Drives the Global Insulin Path Pumps Market
Inkwood Research expects the Global Insulin Patch Pumps Market to surge with a 10.63% CAGR by 2032, and is set to generate $2760.98 million during the forecast period 2023-2032.
Browse 50 market data Tables and 47 Figures spread over 173 Pages, along with an in-depth analysis of the Global Insulin Patch Pumps Market by Type, Delivery Mode, Disease Indication, Distribution Channel, & by Geography.
Refer to the Report Summary Here: https://inkwoodresearch.com/reports/insulin-patch-pumps-market/#report-summary?utm_source=PaidPRNew&utm_medium=OpenPR&utm_campaign=InkwoodPR
This…
Advancing Insulin Delivery Systems boost the Global Insulin Path Pumps Market
Inkwood Research expects the Global Insulin Patch Pumps Market to surge with a 10.63% CAGR by 2032, and is set to generate $2760.98 million during the forecast period 2023-2032.
Browse 50 market data Tables and 47 Figures spread over 173 Pages, along with an in-depth analysis of the Global Insulin Patch Pumps Market by Type, Delivery Mode, Disease Indication, Distribution Channel, & by Geography.
Refer to the Report Summary Here: https://inkwoodresearch.com/reports/insulin-patch-pumps-market/#report-summary
This insightful…
Advancing Insulin Delivery Systems boost the Global Insulin Path Pumps Market
Inkwood Research expects the Global Insulin Patch Pumps Market to surge with a 10.63% CAGR by 2032, and is set to generate $2760.98 million during the forecast period 2023-2032.
Browse 50 market data Tables and 47 Figures spread over 173 Pages, along with an in-depth analysis of the Global Insulin Patch Pumps Market by Type, Delivery Mode, Disease Indication, Distribution Channel, & by Geography.
Refer to the Report Summary Here: https://inkwoodresearch.com/reports/insulin-patch-pumps-market/#report-summary
This insightful…
Insulin Pumps Market Share, Trends and Growth Analysis By Type (Traditional Insu …
Insulin Pumps Market is expected to register a CAGR of 15.5% and acquire the market value of USD 11.5 Billion by 2028 during forecast period 2023-2032. Insulin pumps are discreet, electronic medical devices that can be tucked beneath clothing or fastened to a belt. In order to regulate the rise in blood glucose levels, the pump is used to deliver controlled quantities of insulin within the body at regular intervals…
Insulin Patch Pumps Market Report 2018: Segmentation by Insulin Type (Bolus Insu …
Global Insulin Patch Pumps market research report provides company profile for Roche Holding AG, Cellnovo Group SA, Spring Health Solution Ltd., Debiotech, CeQur SA, Valeritas, Becton Dickenson & Company, Insulet Corporation, Johnson & Johnson, Medtrum Technologies Inc. and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue,…
Insulin pump Market Explore Future Growth 2018-2026 by Global Type-Traditional i …
Insulin pump is a portable device attached to the body that continuously delivers preset amounts of short or rapid acting insulin in the body to control diabetes. Insulin therapy is required in type 1 diabetes and sometime in type 2 diabetes. It serves as an effective alternative to insulin injections. Furthermore, insulin pump delivers the insulin according to the need of body as basal rate, where small amount of insulin…
